Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Hemostatic Effectiveness of SURGICEL® Powder in TKA：a Randomized Controlled Trial

NCT06608992 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT06608992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06608992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Hemostatic Effectiveness of SURGICEL® Powder in TKA：a Randomized Controlled Trial
Lead sponsor
Peking University Third Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
September 28, 2024
Completion date
September 30, 2025
Enrollment
112 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis